Loading clinical trials...
Loading clinical trials...
A Phase 2/3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study With Open-Label Extension (OLE) to Assess the Efficacy and Safety of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Conditions
Interventions
Andecaliximab
Placebo
+1 more
Locations
3
United States
University of California San Francisco (UCSF)
San Francisco, California, United States
Mayo Clinic
Rochester, Minnesota, United States
University of Pennsylvania - Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, United States
Start Date
October 25, 2024
Primary Completion Date
February 4, 2029
Completion Date
February 4, 2029
Last Updated
October 14, 2025
NCT04307953
NCT05394116
NCT05027802
NCT04818398
NCT04665323
NCT02521792
Lead Sponsor
Ashibio Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions